This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: National Institute for Agricultural Research, National Institute of Health and Medical Research, Université Paris Diderot-Paris 7. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 285 
1 out of 1,853 
1 out of 111 
Years Active: 2017
Title: Jean-Michel Sallenave: Innovator in Probiotic Therapy
Introduction
Jean-Michel Sallenave is a notable inventor based in Paris, France. He has made significant contributions to the field of therapy for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). His innovative work focuses on the development of recombinant probiotic bacteria aimed at preventing and treating these conditions.
Latest Patents
Jean-Michel Sallenave holds a patent for "Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)." This invention pertains to the use of specific proteins and their active fractions for therapeutic purposes. The patent details a molecule selected from the trappin-2 protein, WAP family proteins, or Serpin family proteins, which are utilized in the treatment of IBS. Additionally, it describes a recombinant food-grade bacterium that incorporates genes coding for these proteins.
Career Highlights
Throughout his career, Sallenave has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and the Institut National de la Recherche Agronomique. His research has focused on advancing therapeutic options for gastrointestinal disorders, showcasing his commitment to improving patient health.
Collaborations
Jean-Michel Sallenave has collaborated with esteemed colleagues, including Nathalie Vergnolle and Philippe Langella. These partnerships have contributed to the depth and impact of his research in the field of probiotic therapy.
Conclusion
Jean-Michel Sallenave's innovative work in the development of probiotic therapies represents a significant advancement in the treatment of inflammatory bowel disease and irritable bowel syndrome. His contributions continue to influence the field and offer hope for improved health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile